Sanofi | SNY - Equity Capital And Reserves




Sanofi reported 73B in Equity Capital and Reserves for its fiscal quarter ending in September of 2024.

Equity Capital And Reserves Change Date
AbbVie USD 6.07B 750M Dec/2024
Amgen USD 5.88B 1.65B Dec/2024
AstraZeneca USD 40.87B 66M Dec/2024
Bristol-Myers Squibb USD 16.34B 807M Dec/2024
Canopy Growth CAD 509.67M 23.25M Sep/2024
Corcept Therapeutics USD 638.83M 42.59M Sep/2024
Drreddys Laboratories INR 305.34B 10.72B Sep/2024
Eli Lilly USD 14.24B 678M Sep/2024
Galapagos EUR 2.9B 34.37M Dec/2024
Genmab DKK 36.7B 4.78B Dec/2024
GlaxoSmithKline GBP 13.67B 218M Dec/2024
Glaxosmithkline GBP 13.45B 919M Sep/2024
Indivior -167000000 46M Sep/2024
J&J USD 70.16B 1.38B Sep/2024
Merck USD 44.5B 854M Sep/2024
Novartis USD 44.05B 605M Dec/2024
Novartis USD 43.44B 1.71B Sep/2024
Pacira USD 749.58M 129.7M Sep/2024
Perrigo USD 4.57B 20.7M Sep/2024
Pfizer USD 87.98B 0 Sep/2024
Prestige Brands USD 1.79B 56.67M Dec/2024
Roche Holding CHF 36.16B 3.28B Dec/2024
Sanofi 73B 1.36B Jun/2024
Sanofi 73B 0 Sep/2024
Supernus Pharmaceuticals USD 1.01B 49.7M Sep/2024
UCB EUR 8.95B 22M Jun/2024
Zoetis USD 4.77B 464M Dec/2024